enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $23.2857.

Separately, JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of enGene in a report on Tuesday, April 29th.

enGene Stock Performance

NASDAQ:ENGN opened at $3.64 on Wednesday. enGene has a twelve month low of $2.65 and a twelve month high of $11.00. The company has a current ratio of 12.66, a quick ratio of 12.66 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $3.58 and a 200-day moving average of $4.40. The firm has a market cap of $186.00 million, a price-to-earnings ratio of -2.21 and a beta of -0.41.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, June 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.03). Analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enGene

Large investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in enGene during the fourth quarter worth approximately $93,000. Toronto Dominion Bank bought a new position in enGene in the fourth quarter worth $97,000. Cubist Systematic Strategies LLC lifted its position in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after purchasing an additional 2,080 shares during the period. ADAR1 Capital Management LLC bought a new position in enGene in the first quarter worth $107,000. Finally, Corton Capital Inc. bought a new position in enGene in the fourth quarter worth $157,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.